Immuneering Reports Q1 Results, Announces Pivotal Phase 3 Recruitment & Upcoming ASCO Survival Data

summarizeSummary

Immuneering reported improved Q1 financials and reaffirmed its cash runway into 2029, alongside major clinical advancements for its lead pancreatic cancer drug, including pivotal Phase 3 trial recruitment and upcoming new survival data at ASCO.

check_boxKey Events

• Q1 Financials Reported

  Net loss improved to $13.5 million ($0.21 per share) for Q1 2026, compared to $15.0 million ($0.42 per share) for Q1 2025.

• Cash Runway Reaffirmed

  Ended Q1 2026 with $198.6 million in cash, cash equivalents, and marketable securities, with an anticipated cash runway extending into 2029.

• Pivotal Phase 3 Trial Initiated

  The global randomized pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients, with first patient dosing on track for mid-2026.

• Upcoming ASCO Presentation

  New survival data from an expanded cohort of 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in the Phase 2a clinical trial will be presented orally at the 2026 ASCO Annual Meeting on June 1, 2026.

auto_awesomeAnalysis

This 8-K details Immuneering's first-quarter financial results, which show an improved net loss and a reaffirmed cash runway into 2029. Crucially, the company announced significant clinical progress for its lead pancreatic cancer candidate, atebimetinib, including the upcoming presentation of new survival data from an expanded Phase 2a cohort at ASCO and the initiation of patient recruitment for its pivotal Phase 3 trial. These updates provide strong positive momentum for the company's clinical pipeline.